ScienceDex / Researcher record
Kimberly Stegmaier
- Children's Hospital of Philadelphia · Pediatrics (investigator's affiliation)
- Dana-Farber Cancer Institute (no department on record)
From the FY2025 NIH awards this investigator leads as contact PI. The department is the award's.
FY2025 NIH rank #1,565
- Program Leader
- R01 Holder
- Top 10% Funded
- Early Career
- Diverse Portfolio
NIH Funding · FY2025
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
Linked awards ($M)Award-linked rank
View yearly values
| Fiscal year | Linked awards | Records | Rank |
|---|---|---|---|
| 2024 | $3,801,794 | 4 | #1,748 |
| 2025 | $4,706,934 | 5 | #1,565 |
| 2026 | $6,407,402 | 5 | #1,857 |
Award activity
Awards through the years
NIH award records listing this researcher in each fiscal year.
- FY20244 records
- FY2025 · selected5 records
- FY20265 records
Each bar starts at zero. Annual records can include renewals of the same project; they are not a count of distinct career grants.
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID 6772288Search this ID in NIH RePORTER
- ORCID iD
- https://orcid.org/0000-0003-0218-7895Verified identifier for this researcher
- ScienceDex PI coverage
- FY2024 through FY2026Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2027.
FY2025 award records by amount
NIH award records listing Kimberly Stegmaier as a PI. Multi-PI records show the full award amount for context.
- 3OT2CA297572-01S1OT2Contact PIPROTECT (Harnessing PROTEin degradation for Advanced Childhood Tumors)$1.8Maward amount
- $1.1Maward amount
- 5U01CA281840-03U01Co-investigatorImmunotherapeutic targeting of gangliosides in Ewing Sarcoma$767.2Kaward amount
- 5R01CA283395-03R01Contact PIMechanisms of Toxicity Induced by EWS/FLI1 Overdose in Ewing Sarcoma$713.6Kaward amount
- 5P01CA217959-07P01Contact PIDiscovering and Exploiting Mechanisms of Neuroblastoma Therapy ResistanceChildren's Hospital of Philadelphia · Pediatrics (investigator's affiliation)$407.9Kaward amount
Award organizations
Organizations that administered FY2025 awards listing Kimberly Stegmaier as a PI.
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2024First NIH AwardDana-Farber Cancer Institute
- 2024$500K Cumulative Funding
- 2024$1M Cumulative Funding
- 2024$2M Cumulative Funding
- 2024Entered Top 50% NationallyRanked #1748
- 2024Entered Top 25% NationallyRanked #1748
- 2024Entered Top 10% NationallyRanked #1748
- 2025$5M Cumulative Funding
- 2025Multi-Institutional ResearchAwards at 2 institutions
- 2025R01 Grant Holder
- 2025Program/Center Grant Leader
- 2026$10M Cumulative Funding
Shared-award investigators
Other investigators listed on at least one of the same NIH award records as Kimberly Stegmaier.
Miguel Nicolas Rivera
Dana-Farber Cancer Institute
3
shared awards
Robbie G. Majzner
Dana-Farber Cancer Institute
3
shared awards
John M Maris
Children's Hospital of Philadelphia
2
shared awards
Julie R Park
Children's Hospital of Philadelphia
2
shared awards
Robbie G. Majzner
Children's Hospital of Philadelphia
2
shared awards
Shahab Asgharzadeh
Children's Hospital of Philadelphia
2
shared awards
Yael P Mosse
Children's Hospital of Philadelphia
2
shared awards